EconBase
← All authors

Iraj Daizadeh

Takeda (United States) (per OpenAlex) · ORCID · OpenAlex

8 papers in scope · 7 published · 1 on the econ.EM arXiv · 43 citations · h-index 2 (over the papers listed here)

Papers

(1 of 8)

Approval of Drugs With Unmet Trial End Points
published2023 · JAMA Internal Medicine
with Indranil Bhattacharya, A. Robertson
The Impact of US Medical Product Regulatory Complexity on Innovation: Preliminary Evidence of Interdependence, Early Acceleration, and Subsequent Inversion
published2023 · Pharmaceutical Research · 2 citations · first circulated 2022
Why did the number of US FDA medical device guidelines begin to rise in the mid-2010s? A perspective
published2022 · Expert Review of Medical Devices · 2 citations
Singular secular Kuznets-like period realized amid industrial transformation in US FDA medical devices: a perspective on growth from 1976 to 2020
published2022 · Expert Review of Medical Devices · 2 citations
Retraction Note to: Seasonal and Secular Periodicities Identified in the Dynamics of US FDA Medical Devices (1976–2020): Portends Intrinsic Industrial Transformation and Independence of Certain Crises
published2022 · Therapeutic Innovation & Regulatory Science · 2 citations · first circulated 2021
working paper2020 · arXiv · 1 citations
An intellectual property-based corporate strategy: An R&D spend, patent, trademark, media communication, and market price innovation agenda
published2009 · Scientometrics · 24 citations
Issued US patents, patent-related global academic and media publications, and the US market indices are inter-correlated, with varying growth patterns
published2007 · Scientometrics · 10 citations

Assembled from arXiv and OpenAlex. Duplicate records for the same paper are merged, and the published version is shown where we could identify one. Corrections welcome.